Theranexus Société Anonyme (EPA:ALTHX)

Market Cap	23.56M
Revenue (ttm)	2.28M
Net Income (ttm)	-1.77M
Shares Out	8.54M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	6.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,100
Average Volume	466,023
Open	2.700
Previous Close	2.760
Day's Range	2.600 - 2.970
52-Week Range	0.261 - 3.660
Beta	1.83
RSI	62.26
Earnings Date	Sep 25, 2025

About Heartland Financial USA

Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 10
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.